hrs-5965
Small moleculeexperimental
Clinical trial activity
13 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Oct 8, 2022 (NCT05505955)
Timeline
Indications
Mechanism of action
- Complement factor BINHIBITOR
CFB inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07040787 | Phase 1 | Jul 8, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07035665 | Phase 1 | Jun 30, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07014826 | Phase 3 | Jun 4, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06715943 | Phase 3 | Dec 31, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06684041 | Phase 1 | Nov 9, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06674915 | Phase 1 | Nov 5, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06593938 | Phase 3 | Sep 30, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06567392 | Phase 1 | Sep 3, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06490991 | Phase 1 | Jul 17, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06238544 | Phase 2 | Feb 6, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06137768 | Phase 2 | Jan 31, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06051357 | Phase 2 | Nov 15, 2023 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05505955 | Phase 1 | Oct 8, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 13 | 13 | 3 | 2022 |
1 organizations
Page 1 / 1